For nearly 100 years, we have not experienced a shock to the economy where large numbers of industries exhibited disastrous declines in revenues resulting from a pandemic. Frankly, none of us were equipped with readily available valuation frameworks to handle such shocking changes in cash-flow projections, discount rates, the ‘appropriate’ use of comparable companies and the relevant transactions to be used in the M&A comparable method. This panel discussion presents the main valuation parameters that have been affected by the COVID-19 pandemic and the associated legal and experts’ battles, mostly during and post-pandemic.